HTG Molecular Diagnostics, Inc.
HTGMQ
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.06M
Close$
Share Statistics
| Market cap | $1.06 Million |
|---|---|
| Enterprise Value | $2.05 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-24.28 |
| Beta | 2.76 |
| Outstanding Shares | 2,214,082 |
Return
| Return on Equity | -4246.92% |
|---|---|
| Return on Assets | -185.46% |
| Return on Invested Capital | -460.72% |
Valuation & Multiples
| P/E Ratio | 0 |
|---|---|
| PEG | 0 |
| Price to Sales | 0.0 |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 0.33 |
| Enterprise Value to EBIT | -0.1 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 1.94 |
| Debt to Equity | 8.39 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 29, 2026
EPS Estimate
$-11.80
Average shareholder expectationRevenue Estimate
$1.60 M
Average shareholder expectationNext Earnings Call
Expected Date
August 14, 2026
EPS Estimate
$-11.80
Average shareholder expectationRevenue Estimate
$1.60 M
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About HTG Molecular Diagnostics, Inc.
53 employees
CEO: John L. Lubniewski HTG Molecular Diagnostics, Inc. a life sciences company, focuses on the precision medicine. The company offers instruments; consumables; and software that automate sample processing and profiles various molecular targets. Its marketed mo...